Retatrutide: what the triple-agonist data actually shows

Three receptors, not two

Retatrutide (LY3437943) is a single molecule that agonises three G-protein-coupled receptors: GIP, GLP-1 and glucagon.

The first two it shares with tirzepatide. The glucagon receptor is the distinguishing feature, and it is the one that makes retatrutide mechanistically distinct rather than incrementally stronger.

What the glucagon receptor contributes

Glucagon receptor activation increases hepatic energy expenditure and promotes lipid oxidation. This runs alongside, rather than through, the satiety and insulin-secretion pathways engaged by GLP-1 and GIP.

The result is that energy balance is influenced from two directions at once — intake and expenditure — which is not achievable through incretin receptors alone. This is the pharmacological rationale for the triple-agonist class.

It is also why glucagon agonism was historically avoided: activating it in isolation raises hepatic glucose output. The design premise of retatrutide is that concurrent GLP-1 and GIP agonism offsets that effect.

The published record

Phase 2 results were published in the New England Journal of Medicine in 2023. That is the substantive peer-reviewed dataset available for this compound.

Two things follow. First, phase 2 establishes mechanism and dose-response, not long-term safety — that is what phase 3 exists to test. Second, any claim about retatrutide that goes beyond the phase 2 record is extrapolation, however frequently repeated.

For research purposes this makes retatrutide interesting precisely because the picture is incomplete. It is a compound where comparative work against mono- and dual-agonists still has room to contribute.